Antithrombin-lowering in hemophilia: a closer look at fitusiran

Frontiers The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A

Frontiers Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications

International consensus recommendations on the management of people with haemophilia B - Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d'Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon

Non‐factor therapies for bleeding disorders: A primer for the general haematologist - Swan - 2022 - eJHaem - Wiley Online Library

Fitusiran Prophylaxis in Hemophilia With or Without Inhibitors

Fitusiran prophylaxis reduced bleeds by 61% in people with Hem A or B - Hemophilia Federation of America

Hemostatic disorders and hereditary angioedema

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet

Fitusiran Prophylaxis for Patients With Hemophilia A or B

Fitusiran prophylaxis 'great option' for reducing bleeds in people with hemophilia A or B

IJMS, Free Full-Text

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial - The Lancet Haematology